Valuation: Regeneron Pharmaceuticals, Inc.

Market Cap 93.11B 506B 83.39B 76.71B 69.5B 130B 8,841B 132B 915B 367B 4,651B 349B 342B 14,666B P/E 2026 *
14.4x
P/E 2027 * 16.2x
Enterprise Value 85.69B 465B 76.74B 70.59B 63.96B 120B 8,136B 122B 842B 338B 4,280B 322B 315B 13,497B EV / Sales 2026 *
4.87x
EV / Sales 2027 * 4.17x
Free-Float
71.06%
Yield 2026 *
0.43%
Yield 2027 * 0.46%
1 day+15.11%
1 week+25.10%
1 month+27.91%
3 months+30.26%
6 months+43.73%
Current year+18.07%
1 week 71.76
Extreme 71.76
84.06
1 month 60.22
Extreme 60.22
84.06
Current year 50
Extreme 50
84.06
1 year 50
Extreme 50
84.06
3 years 44.82
Extreme 44.82
111.72
5 years 44.82
Extreme 44.82
111.72
10 years 18.16
Extreme 18.160832
111.72
Manager TitleAgeSince
President 66 2000-12-31
Chief Executive Officer 73 1988-01-07
Director of Finance/CFO 55 2024-02-04
Director TitleAgeSince
Chairman 73 2023-06-08
Director/Board Member 85 1991-05-31
Director/Board Member 76 1988-01-07
Change 5-day change 1-year change 3-year change Capi.($)
+15.11%+25.10% - - 92.65B
+3.19%+11.31%+64.28%+155.91% 1,263B
-0.73%+3.56%+44.65%+84.17% 658B
+1.41%+3.24%+35.25%+108.88% 521B
+0.42%+3.20%+55.81%+72.50% 391B
+2.18%+2.93%+73.90%+45.59% 369B
+1.12%+4.52%+34.76%+58.24% 307B
+6.96%+8.86%+11.95%+36.20% 290B
+1.15%+6.09%+56.15%+82.25% 252B
+3.06%+9.38%+42.48%+117.32% 212B
Average +3.39%+5.90%+46.58%+84.56% 473.55B
Weighted average by Cap. +2.29%+6.60%+50.51%+100.44%

Financials

2026 *2027 *
Net sales 17.6B 95.59B 15.77B 14.5B 13.14B 24.56B 1,672B 25.02B 173B 69.43B 879B 66.07B 64.66B 2,773B 19.59B 106B 17.54B 16.14B 14.62B 27.33B 1,860B 27.84B 192B 77.25B 978B 73.51B 71.95B 3,085B
Net income 6.88B 37.34B 6.16B 5.67B 5.13B 9.6B 653B 9.78B 67.56B 27.12B 343B 25.81B 25.26B 1,083B 6.12B 33.22B 5.48B 5.04B 4.57B 8.54B 581B 8.69B 60.1B 24.12B 306B 22.96B 22.47B 964B
Net Debt -7.42B -40.31B -6.65B -6.12B -5.54B -10.36B -705B -10.55B -72.93B -29.28B -371B -27.86B -27.27B -1,169B -11.48B -62.33B -10.28B -9.46B -8.57B -16.02B -1,090B -16.32B -113B -45.27B -573B -43.08B -42.16B -1,808B
Projected Income Statement - Annual - Regeneron Pharmaceuticals, Inc.
Logo Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from collaboration agreements (51.1%): collaboration with Sanofi (80.3% of revenues), Bayer (19.4%) and other (0.3%); - revenues from product sales (30%); - revenues from sales of technology licenses and subcontracted research services (4.9%). At the end of 2025, the group had a portfolio of approximately 45 products in clinical development.
Employees
15,410
Date Price Change Volume
26-10-30 R$83.72 +15.11% 856
26-10-28 R$72.73 +0.68% 215
26-10-27 R$72.24 -0.48% 734
26-10-26 R$72.59 +8.47% 3,596
26-10-23 R$66.92 -3.24% 8,845
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Regeneron Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
927.89USD
Average target price
924.00USD
Spread / Average Target
-0.42%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Regeneron Pharmaceuticals, Inc.